BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33333624)

  • 1. Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients.
    Khader A; Chang SC; Santamaria-Barria J; Garland-Kledzik M; Scholer A; Goldfarb M; Grumley J; Fischer T
    J Surg Oncol; 2021 Mar; 123(4):854-865. PubMed ID: 33333624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Nakamura R; Yamamoto N; Miyaki T; Itami M; Shina N; Ohtsuka M
    Breast Cancer; 2018 Jan; 25(1):86-93. PubMed ID: 28735457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
    Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
    Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer.
    Ahlgren J; Holmberg L; Bergh J; Liljegren G
    Eur J Surg Oncol; 2002 Mar; 28(2):97-102. PubMed ID: 11884042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel Node Biopsy in Early Breast Cancer Patients with Palpable Axillary Node.
    Shojaee L; Abedinnegad S; Nafisi N; Naghshvar F; Godazandeh G; Moradi S; Shakeri Astani K; Godazandeh Y
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1631-1636. PubMed ID: 32592357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel node biopsy in breast cancer has a greater node positivity rate than axillary node sample: results from a retrospective analysis.
    Macaskill EJ; Dewar S; Purdie CA; Brauer K; Baker L; Brown DC
    Eur J Surg Oncol; 2012 Aug; 38(8):662-9. PubMed ID: 22592099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Ramzi S; Najeeb E; Coulthard J; Jenkins S
    Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
    Shin YD; Lee HM; Choi YJ
    BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
    Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
    Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much does axillary ultrasound contribute in women undergoing breast-conserving surgery with no palpable axillary nodes?
    Preda T; McGrath R; Bingham J; Fawcett A; O'Dea C; Bochner M; Gill PG; Kollias J
    ANZ J Surg; 2020 Jun; 90(6):1146-1150. PubMed ID: 31957192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
    Mann JM; Wu X; Christos P; Nagar H
    Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer.
    Pargaonkar AS; Beissner RS; Snyder S; Speights VO
    Arch Pathol Lab Med; 2003 Jun; 127(6):701-5. PubMed ID: 12741893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
    Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
    Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.